Aripiprazole (Abilify) Use in First Trimester: Proceed with Caution
Aripiprazole can be used during the first trimester of pregnancy when the benefits of treating severe psychiatric illness outweigh potential risks, but you must counsel patients about possible lactation failure postpartum and monitor neonates for withdrawal symptoms.
Evidence-Based Safety Profile
The FDA drug label for Abilify states that "overall available data from published epidemiologic studies of pregnant women exposed to aripiprazole have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal outcomes" 1. This is reassuring regarding teratogenicity.
The most robust prospective data comes from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics, which followed 158 women with first-trimester aripiprazole exposure. After adjusting for confounding variables, the risk of major malformations was not significantly elevated compared to controls (adjusted OR 1.35,95% CI 0.43-4.20) 2. A systematic review of 100 first-trimester exposures found a malformation rate of 5.0%, with a relative risk of 1.4 (95% CI 0.5-3.1), which was not statistically significant 3.
Critical Clinical Considerations
Neonatal Monitoring is Mandatory
Neonates exposed to antipsychotics including Abilify during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorders 1. These symptoms vary in severity—some resolve within hours while others require prolonged hospitalization. You must arrange for neonatal monitoring and be prepared to manage these symptoms.
Lactation Failure is a Major Concern
Aripiprazole exposure during pregnancy may significantly decrease milk supply in the postpartum period 1. Recent data from Indian perinatal psychiatry services found that 74% of women continuing aripiprazole through pregnancy and postpartum experienced complete lactation failure, with an additional 11% having insufficient milk production 4. Multiple case reports confirm this pattern 5, 6. This must be discussed with patients during pregnancy planning so they can make informed decisions about infant feeding.
Pregnancy Complications to Monitor
While metabolic risks appear low, one Australian study found associations with pregnancy hypertension, lower birth weight, shorter gestation, and higher neonatal admission rates 7. A large Taiwanese cohort study showed increased risk of preterm birth (adjusted HR 1.29,95% CI 1.04-1.60) but no increased risk of gestational diabetes 8.
Decision-Making Algorithm
When psychiatric illness is severe (schizophrenia, bipolar disorder, major depression):
- Continue aripiprazole if already stable on it
- The risk of untreated illness (relapse, hospitalization, suicide) outweighs the modest fetal risks
- Use the lowest effective dose
Key counseling points before conception or in early pregnancy:
- No clear evidence of increased major malformations
- High likelihood (>70%) of lactation failure—plan for formula feeding
- Neonate will need monitoring for withdrawal symptoms at birth
- Increased risk of preterm birth and possibly lower birth weight
- Monitor for pregnancy hypertension
Avoid if possible in first trimester only when:
- Psychiatric illness is mild and can be managed without medication
- Patient can be safely transitioned to alternative with better pregnancy data
- Patient prioritizes breastfeeding and is willing to accept relapse risk
Common Pitfalls
Do not discontinue aripiprazole abruptly in a stable patient upon discovering pregnancy—the risk of psychiatric decompensation is substantial. Women who discontinued antidepressants during pregnancy had significantly higher relapse rates of major depression 1. The same principle applies to antipsychotics in severe mental illness.
Do not assume all atypical antipsychotics have equivalent pregnancy profiles. While aripiprazole data are reassuring for malformations, its unique dopamine partial agonist mechanism may explain the high lactation failure rate compared to other agents.
Register all exposures with the National Pregnancy Registry for Atypical Antipsychotics (1-866-961-2388) to contribute to the evidence base 1.